Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Dovitinib in Progressive Pancreatic Neuroendocrine Tumors
NCT02108782Phase 2Withdrawn
- Sponsor
- Academic and Community Cancer Research United
- Start
- Oct 2014
- Primary completion
- May 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of dovitinib in Pancreatic neuroendocrine tumor (PanNET), sponsored by Academic and Community Cancer Research United. Planned start Oct 2014; status: withdrawn.
02
Drugs
dovitinib
03
Conditions
Pancreatic neuroendocrine tumor (PanNET)
Beyond the preview
Go deeper on NCT02108782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02108782.